Literature DB >> 15006703

Astrocytic beta2-adrenergic receptors and multiple sclerosis.

Jacques De Keyser1, Esther Zeinstra, Nadine Wilczak.   

Abstract

Despite intensive research, the cause and a cure of multiple sclerosis (MS) have remained elusive and many aspects of the pathogenesis are not understood. Immunohistochemical experiments have shown that astrocytic beta(2)-adrenergic receptors are lost in MS. Because norepinephrine mediates important supportive and protective actions of astrocytes via activation of these beta(2)-adrenergic receptors, we postulate that this abnormality may play a prominent role in the pathogenesis of MS. First, it may allow astrocytes to act as facultative antigen-presenting cells, thereby initiating T-cell mediated inflammatory responses that lead to the characteristic demyelinated lesions. Second, it may contribute to inflammatory injury by stimulating the production of nitric oxide and proinflammatory cytokines, and reducing glutamate uptake. Third, it may lead to apoptosis of oligodendrocytes by reducing the astrocytic production of trophic factors, including neuregulin, nerve growth factor and brain-derived neurotrophic factor. Fourth, it may impair astrocytic glycogenolysis, which supplies energy to axons, and this may represent a mechanism underlying axonal degeneration that is hold responsible for the progressive chronic disability.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15006703     DOI: 10.1016/j.nbd.2003.10.012

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  18 in total

Review 1.  G protein-coupled receptors as therapeutic targets for multiple sclerosis.

Authors:  Changsheng Du; Xin Xie
Journal:  Cell Res       Date:  2012-06-05       Impact factor: 25.617

Review 2.  Astrocyte, the star avatar: redefined.

Authors:  Pankaj Seth; Nitin Koul
Journal:  J Biosci       Date:  2008-09       Impact factor: 1.826

3.  Astrocyte-neuron interactions in neurological disorders.

Authors:  G Ricci; L Volpi; L Pasquali; L Petrozzi; G Siciliano
Journal:  J Biol Phys       Date:  2009-05-14       Impact factor: 1.365

Review 4.  White-matter astrocytes, axonal energy metabolism, and axonal degeneration in multiple sclerosis.

Authors:  Melissa Cambron; Miguel D'Haeseleer; Guy Laureys; Ralph Clinckers; Jan Debruyne; Jacques De Keyser
Journal:  J Cereb Blood Flow Metab       Date:  2012-01-04       Impact factor: 6.200

5.  Amygdala transcriptome and cellular mechanisms underlying stress-enhanced fear learning in a rat model of posttraumatic stress disorder.

Authors:  Igor Ponomarev; Vinuta Rau; Edmond I Eger; R Adron Harris; Michael S Fanselow
Journal:  Neuropsychopharmacology       Date:  2010-02-10       Impact factor: 7.853

Review 6.  Glial-neuronal interactions--implications for plasticity and drug addiction.

Authors:  Sukumar Vijayaraghavan
Journal:  AAPS J       Date:  2009-02-24       Impact factor: 4.009

7.  Fingolimod Suppresses the Proinflammatory Status of Interferon-γ-Activated Cultured Rat Astrocytes.

Authors:  Saša Trkov Bobnar; Matjaž Stenovec; Katarina Miš; Sergej Pirkmajer; Robert Zorec
Journal:  Mol Neurobiol       Date:  2019-01-30       Impact factor: 5.590

Review 8.  Adrenergic and dopaminergic modulation of immunity in multiple sclerosis: teaching old drugs new tricks?

Authors:  Marco Cosentino; Franca Marino
Journal:  J Neuroimmune Pharmacol       Date:  2012-10-17       Impact factor: 4.147

9.  Genetic suppression of β2-adrenergic receptors ameliorates tau pathology in a mouse model of tauopathies.

Authors:  Elena V Wisely; Yang K Xiang; Salvatore Oddo
Journal:  Hum Mol Genet       Date:  2014-03-13       Impact factor: 6.150

10.  Association between change in normal appearing white matter metabolites and intrathecal inflammation in natalizumab-treated multiple sclerosis.

Authors:  Johan Mellergård; Anders Tisell; Olof Dahlqvist Leinhard; Ida Blystad; Anne-Marie Landtblom; Kaj Blennow; Bob Olsson; Charlotte Dahle; Jan Ernerudh; Peter Lundberg; Magnus Vrethem
Journal:  PLoS One       Date:  2012-09-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.